Medicine safety

We are committed to the safety of our medicines in all cases, and maintain an active pharmacovigilance programme to help ensure this.

Through our robust commitment to pharmacovigilance, we ensure we remain focused on patients' safety. Our Pharmacovigilance Department manages a pharmacovigilance system for the collection, collation, and evaluation of adverse events and the implementation of effective corrective and preventive actions.

For medical information enquiries, complaints and adverse events reporting, contact: pv@hikma.com

In Canada, you can also contact: Canada_DrugSafety@hikma.com 

In the US, you can also contact: us.hikma@primevigilance.com or call +1-877-845-0689 or 1-800-962-8364, or you can contact the FDA directly at 1-800-FDA-1088 or www.fda.gov/medwatch

In the EU, you can also contact:   portugaleupharmacovigilance@hikma.com or call +351 939 610 004

In France, you can also contact: francepv@hikma.com

In Germany, you can also contactdl-muc-qs@hikma.com

Last reviewed on 30 May 2022